Genetic Toxicology Testing Market Picks Up Pace Owing to Increasing Drug R&D Spending

 

Genetic Toxicology Testing Market

Genetic toxicology testing involves assessment of chemicals, products, or environmental samples for potential genetic toxicity. It plays a crucial role in drug discovery by evaluating drug safety and genetic risk associated with exposure. Genetic toxicology assays are carried out at various stages of drug development including lead optimization and preclinical safety assessment. Growing drug research and development activities along with stringent regulations have been boosting the genetic toxicology testing market.

The global genetic toxicology testing market is estimated to be valued at US$ 3.33 Bn in 2024 and is expected to exhibit a CAGR of 13% over the forecast period of 2024 to 2031. 

Genetic Toxicology Testing Market Demand  helps determine the mutagenic and clastogenic potential of new chemical entities which is important for monitoring drug safety. It evaluates chromosomal abnormalities, gene mutations and other DNA damages caused due to drug exposure. Increasing investments in pharmaceutical R&D and adoption of predictive toxicology approaches is fueling demand for genetic toxicology assays.

Key Takeaways

Key players operating in the genetic toxicology testing are Thermo Fisher Scientific, Charles River, Creative Bioarray, Laboratory Corporation of America Holdings, Jubilant Life Sciences, and others.

The global expansion of key players through strategic acquisitions and partnerships is helping increase geographic footprint and service offerings. For instance, in 2021, Charles River acquired Vigene Biosciences to expand its gene therapy research models and services capabilities.

North America dominated the genetic toxicology testing market in 2020 owing to presence of large pharmaceutical companies and supportive regulatory environment for drug development in the region. However, Asia Pacific is expected to witness highest growth during the forecast period due to increasing R&D spending and low operational costs.

Rising investments in pharmaceutical Research & Development activities: Stringent drug approval regulations mandate genetic toxicology studies right from the early research stages. Growing R&D spending by biotech and pharma companies on novel drug development is driving increased adoption of genetic toxicology testing services and products.

Shortage of skilled professionals in life science research: Conducting genetic toxicology studies requires specialized expertise in fields of molecular and cell biology, genetics, and bioinformatics. Global shortage of skilled life science researchers poses a major challenge for laboratory expansion and new service offerings. Lack of expertise can also negatively impact result interpretation and assessment of genetic toxicity.

Market Drivers

Stringent safety regulations for drug development: Stringent guidelines by regulatory bodies have made genetic toxicology studies compulsory for assessing genotoxic impurities, mutagenic potential and chromosomal damage risks of new chemical entities. Strict mandates are fueling adoption of genetic toxicology testing services.

Technological advancements: Continuous development of high-throughput screening platforms, automated liquid handling systems, and next-gen sequencing techniques are helping evaluate genetic toxicity faster and more efficiently. Adoption of new technologies is stimulating market revenues.

Market Restrains

High costs associated with genetic toxicology studies: Genetic Toxicology Testing Market Size And Trends assays require specialized equipment, trained personnel, and involve complex study protocols making them capital intensive. Additionally, assays like in vivo studies involve use of large number of animals driving up costs.

Shortage of skilled professionals in life science research: Conducting genetic toxicology studies requires specialized expertise in fields of molecular and cell biology, genetics, and bioinformatics. Global shortage of skilled life science researchers poses a major challenge for laboratory expansion and new service offerings. Lack of expertise can also negatively impact result interpretation and assessment of genetic toxicity.
Segment Analysis

The in vitro segment dominates the genetic toxicology testing market, accounting for over 60% market share. In vitro tests are preferred over in vivo tests due to their cost effectiveness, high-throughput screening ability, and ability to reduce/replace animal testing. The in vitro segment is expected to continue dominating during the forecast period owing to stringent safety regulations mandating pre-screening of chemicals and drugs using in vitro assays prior to animal and human testing.

Global Analysis

North America dominates the global genetic toxicology testing market, accounting for over 35% of the market revenue. Stringent safety regulations pertaining to chemical, pharmaceutical and cosmetic products imposed by regulatory bodies such as the FDA drive significant demand for genetic toxicology testing in the region. presence of major CROs and leading pharmaceutical companies conducting extensive R&D for new drug development also contributes to the large market share of the North America region. The Asia Pacific region is expected to record the highest growth during the forecast period owing to increasing drug development activities by pharmaceutical players and rising biotechnology research in major Asia Pacific countries including China and India.

Get More Insights On, Genetic Toxicology Testing Market

About Author:

Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc. (https://www.linkedin.com/in/money-singh-590844163)